ArticleFrontiers in cell and developmental biology2026
Ophthalmic screening in phakomatoses.
Article in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Phakomatoses are a heterogenous group of congenital neurocutaneous syndromes that are associated with a wide range of ocular and systemic presentations. The ocular conditions are important to consider as they may be asymptomatic early on, but progress to irreversible vision loss. Due to the variability of disease presentation, timely diagnosis is crucial to preserve visual outcomes. This article provides a comprehensive review of literature on nine major phakomatoses, including Neurofibromatosis type 1, Neurofibromatosis type 2, Tuberous Sclerosis complex, Sturge Weber syndrome, Von Hippel-Lindau, Ataxia Telangiectasia, Basal Cell Nevus Syndrome, Wyburn-Mason syndrome, and PHACE syndrome, which are commonly treated by ophthalmologists and other eye care professionals. Across these syndromes, some common vision threatening manifestation include glaucoma, optic pathway gliomas, and retinal hamartomas, with variability in the age of onset and disease progression. This article aims to provide syndrome specific screening guidelines to allow early detection of ocular pathology and promote multi-disciplinary care among ophthalmologists, pediatricians, and other providers to decrease visual morbidities and improve overall patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.